标题
Met in Urological Cancers
作者
关键词
-
出版物
Cancers
Volume 6, Issue 4, Pages 2387-2403
出版商
MDPI AG
发表日期
2014-12-16
DOI
10.3390/cancers6042387
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin
- (2015) Sherri Z. Millis et al. Clinical Genitourinary Cancer
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression
- (2014) Yang Peng et al. BIOSCIENCE REPORTS
- A DNA aptamer to c-Met inhibits cancer cell migration
- (2014) R. Ueki et al. CHEMICAL COMMUNICATIONS
- c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer
- (2014) Daniel Delitto WORLD JOURNAL OF GASTROENTEROLOGY
- The tumour suppressor miR-34c targets MET in prostate cancer cells
- (2013) Z Hagman et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor
- (2013) Sachiyo Nishida et al. CANCER SCIENCE
- The emerging role of MET/HGF inhibitors in oncology
- (2013) Giorgio V. Scagliotti et al. CANCER TREATMENT REVIEWS
- Thrombospondin-1 in Urological Cancer: Pathological Role, Clinical Significance, and Therapeutic Prospects
- (2013) Yasuyoshi Miyata et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- From AR to c-Met: Androgen deprivation leads to a signaling pathway switch in prostate cancer cells
- (2013) TIANCHENG LIU et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- The Current State of Molecularly Targeted Drugs Targeting HGF/Met
- (2013) S. Yano et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
- (2013) M. Dror Michaelson et al. JOURNAL OF CLINICAL ONCOLOGY
- Developing biomarkers to predict benefit from HGF/MET pathway inhibitors
- (2013) Hartmut Koeppen et al. JOURNAL OF PATHOLOGY
- c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
- (2012) G. T. Gibney et al. ANNALS OF ONCOLOGY
- Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
- (2012) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
- (2012) David C. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Abstract A233: Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone.
- (2012) F. Schimmoller et al. MOLECULAR CANCER THERAPEUTICS
- A Meta-Analysis of the Relationship between FGFR3 and TP53 Mutations in Bladder Cancer
- (2012) Yann Neuzillet et al. PLoS One
- Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer
- (2012) Umesh T. Sankpal et al. PROSTATE
- High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer
- (2012) FRANK JACOBSEN et al. Experimental and Therapeutic Medicine
- Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer
- (2011) Chen-Yun Yeh et al. BMC CANCER
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Unknown
- (2011) Minja Pfeiffer et al. MOLECULAR MEDICINE
- Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer
- (2011) Geert J. L. H. van Leenders et al. PLoS One
- Effects of transferred NK4 gene on proliferation, migration, invasion and apoptosis of human prostate cancer DU145 cells
- (2010) Dan Yue et al. ASIAN JOURNAL OF ANDROLOGY
- Efficacy of c-Met inhibitor for advanced prostate cancer
- (2010) William H Tu et al. BMC CANCER
- A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
- (2010) J. P. Eder et al. CLINICAL CANCER RESEARCH
- Clinical implications ofMETgene copy number in lung cancer
- (2010) Luca Toschi et al. Future Oncology
- MET signalling: principles and functions in development, organ regeneration and cancer
- (2010) Livio Trusolino et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting the Met signaling pathway in renal cancer
- (2009) Alessio Giubellino et al. Expert Review of Anticancer Therapy
- Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase–2 and –7 and E-cadherin
- (2009) Yasuyoshi Miyata et al. HUMAN PATHOLOGY
- Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines
- (2009) K A Olaussen et al. ONCOGENE
- In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue
- (2009) Natalia Guzmán-Ramírez et al. PROSTATE
- A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
- (2008) W. L. Dahut et al. CLINICAL CANCER RESEARCH
- Prognostic Value of MET, RON and Histoprognostic Factors for Urothelial Carcinoma in the Upper Urinary Tract
- (2008) E. Compérat et al. JOURNAL OF UROLOGY
- Androgen receptor is a tumor suppressor and proliferator in prostate cancer
- (2008) Y. Niu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search